Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
Galcanezumab is as effective and well-tolerated in patients aged ≥65 years as in younger patients but older patients showed a higher rate of excellent response. Age is associated with a better response to galcanezumab.
Authors
- Ane Mínguez‐Olaondo (ORCID: https://orcid.org/0000-0002-7742-3920)
- A. López-Bravo (ORCID: https://orcid.org/0000-0002-2465-2316)
- Fernando Velasco Juanes
- David García‐Azorín (ORCID: https://orcid.org/0000-0002-3132-1064)
- Aintzine Ruisánchez
- Ángel L. Guerrero (ORCID: https://orcid.org/0000-0001-7493-6002)
- Sonsoles Aranceta
- Vı́ctor Obach (ORCID: https://orcid.org/0000-0002-0518-1053)
- Daniel Guisado‐Alonso (ORCID: https://orcid.org/0000-0002-5799-3184)
- M. Martín Bujanda
- Elisa Cuadrado‐Godia
- Julia Peris‐Subiza (ORCID: https://orcid.org/0009-0002-4393-5861)
- Natalia Roncero
- Amaya Echeverría
- Rocío Álvarez Escudero
Institutions
- Universidad de Valladolid (ES)
- Universidad de Deusto (ES)
- Universitat Pompeu Fabra (ES)
- Hospital de Basurto (ES)
- Biogipuzkoa Health Research Institute (ES)
- Hospital Universitario Araba (ES)
- Hospital Clínic de Barcelona (ES)
- Corporació Sanitària Parc Taulí (ES)
- Hospital de Galdakao (ES)
- Navarrabiomed (ES)
- Hospital Universitario Reina Sofía (ES)
- Osakidetza (ES)
- Hospital Universitario Central de Asturias (ES)
- Hospital de Cruces (ES)
- Donostiako Unibertsitate Ospitalea (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Río Hortega (ES)
- Universitat de Barcelona (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1111/head.15064
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- H. Lundbeck A/S